Cover Image
Market Research Report
Product code 
1039414

Migraine - Global Drug Forecast and Market Analysis to 2030

Published: | GlobalData | 131 Pages | Delivery time: 1-2 business days

Price

Back to Top
Migraine - Global Drug Forecast and Market Analysis to 2030
Published: November 18, 2021
GlobalData
Content info: 131 Pages
Delivery time: 1-2 business days
  • Description
  • Table of Contents
  • List of Tables

Migraine is a complex neurological condition characterized by frequent headaches that can last between four and 72 hours. The pain is often unilateral and pulsating in nature, which can often be worsened by physical activity. In most cases, migraine is associated with symptoms such as photophobia, phonophobia, osmophobia, nausea, vomiting, loss of appetite, and sometimes sensory disturbances.

The two clinically and commercially relevant segments considered for the classification of migraine in this report are patients with episodic migraine, who suffer up to 14 migraines per month, and patients with chronic migraine, who suffer 15 or more attacks per month.

For patients that experience four or more migraine attacks per month, physicians look to prescribe a preventive treatment. Preventive treatment is considered an additive to acute therapy and minimizes the risk of medication overuse headaches associated with Nonsteroidal anti-inflammatory drug (NSAID) and triptan treatment.

The migraine market in the 7MM was valued at $4.7B in the 2020 baseline year. GlobalData anticipates that over the 10-year forecast period, the market is projected to grow at a Compound Annual Growth Rate (CAGR) of 9.9%, reaching $12.0B by 2030. The major driver for this growth will be the increased prescription of calcitonin gene-related peptide (CGRP) antagonists, gepants, and monoclonal antibodies (mAbs). In addition, the launch of five new pipeline products which will have higher annual costs of therapy (ACOTs) when compared with the cost of the most commonly used migraine treatments, will drive further growth into this market. In order of entry, these products will include Axsome Therapeutics' AXS-07, Zosano Pharma's Qtrypta, Biohaven Pharmaceutical's zavegepant (intranasal), Satsuma Pharmaceuticals' STS101, and Biohaven Pharmaceutical's zavegepant (oral).

Key Highlights

  • The prevalence of migraine is increasing in line with population growth in the 7MM.
  • Oral triptans are the first-line therapy for acute migraine treatment. First-line therapies for migraine prophylaxis depend on the patients' comorbidities and include anti-epileptic agents, antidepressants, beta blockers, and angiotensin receptor blockers.
  • The greatest unmet need in the migraine market is access to effective and tolerable prophylactic treatments, in addition to the need for more efficacious acute therapy options.
  • The migraine pipeline is dominated by reformulations of mature products with novel delivery devices that provide preferable route of administration to patients.
  • The migraine market will exhibit significant growth between 2020 and 2030, driven by the increased prescription of anti-CGRP mAbs and small molecule CGRP antagonists, gepants.

Key Questions Answered

  • What are the key migraine treatments available in 2020?
  • When will the late stage pipeline products launch, and how will it affect drug sales and the overall migraine market in the 7MM?
  • Which unmet needs will remain unaddressed in the forecast period and what opportunities remain for pharmaceutical companies?

Scope

  • Overview of migraine, including epidemiology, symptoms, diagnosis, and disease management.
  • Annualized migraine therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in two patient segments (episodic migraine and chronic migraine) forecast from 2020 to 2030.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the migraine therapeutics market.
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for migraine treatment. The most promising candidates in Phase III development are profiled.
  • Analysis of the current and future market competition in the global migraine therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global migraine therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global migraine therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Product Code: GDHC224PIDR

Table of Contents

Table of Contents

1 Migraine: Executive Summary

  • 1.1 Migraine Therapeutics Market will grow to $12.0B
  • 1.2 Key Players Will Maintain Their Competitive Position
  • 1.3 Access to Effective and Tolerable Prophylactic Treatments and Additional Acute Therapy Options Remain Unmet Needs
  • 1.4 The Gepants Are the Most Promising New Entrants to the Migraine Market
  • 1.5 What Do Physicians Think?

2 Introduction

  • 2.1 Catalyst
  • 2.2 Related Reports
  • 2.3 Upcoming Reports

3 Disease Overview

  • 3.1 Etiology and Pathophysiology
    • 3.1.1 Etiology
    • 3.1.2 Pathophysiology
  • 3.2 Classification or Staging Systems
    • 3.2.1 Premonitory Phase
    • 3.2.2 Aura Phase
    • 3.2.3 Headache Phase
    • 3.2.4 Resolution Phase

4 Epidemiology

  • 4.1 Disease Background
  • 4.2 Risk Factors and Comorbidities
  • 4.3 Global and Historical Trends
  • 4.4 7MM Forecast Methodology
    • 4.4.1 Sources Used
    • 4.4.2 Forecast Assumptions and Methods
    • 4.4.3 Forecast Assumptions and Methods: 12-Month Total Prevalent Cases of Migraine
    • 4.4.4 Forecast Assumptions and Methods: 12-Month Total Prevalent Cases of Migraine by Frequency
    • 4.4.5 12-Month Total Prevalent Cases of Migraine by Type
    • 4.4.6 12-Month Diagnosed Prevalent Cases of Migraine
  • 4.5 Epidemiological Forecast for Migraine (2020-2030)
    • 4.5.1 12-Month Total Prevalent Cases of Migraine
    • 4.5.2 Age-Specific 12-Month Total Prevalent Cases of Migraine
    • 4.5.3 Sex-Specific 12-Month Total Prevalent Cases of Migraine
    • 4.5.4 12-Month Total Prevalent Cases of Migraine by Frequency of Episodic and Chronic
    • 4.5.5 12-Month Total Prevalent Cases of Migraine by Type
    • 4.5.6 12-Month Diagnosed Prevalent Cases of Migraine
  • 4.6 Discussion
    • 4.6.1 Epidemiological Forecast Insight
    • 4.6.2 COVID-19 Impact
    • 4.6.3 Limitations of the Analysis
    • 4.6.4 Strengths of the Analysis

5 Disease Management

  • 5.1 Diagnosis and Treatment Overview
    • 5.1.1 Episodic Migraine
    • 5.1.2 Chronic Migraine
  • 5.2 Additional KOL Insights on Disease Management

6 Competitive Assessment

  • 6.1 Overview

7 Unmet Needs and Opportunity Assessment

  • 7.1 Overview
  • 7.2 Acute Therapies for Patients with, or at Risk of, Cardiovascular Disorders
  • 7.3 Limited Acute Therapies for Patients Unresponsive to Triptan Medication
  • 7.4 Access to Effective and Tolerable Prophylactic Treatments
  • 7.5 Physician Education for Diagnosis
  • 7.6 Raise Awareness of the Disease in the General Population

8 R&D Strategies

  • 8.1 Overview
    • 8.1.1 Gepants for Dual-Acting Acute and Preventive Indications
    • 8.1.2 Preventive Drugs with Long Duration of Action
    • 8.1.3 Improving Efficacy of Marketed Migraine Drugs
    • 8.1.4 Novel MOAs
  • 8.2 Clinical Trials Design
    • 8.2.1 Study Design
    • 8.2.2 Endpoints for Migraine Clinical Trials
    • 8.2.3 Patient Recruitment

9 Pipeline Assessment

  • 9.1 Overview
  • 9.2 Promising Drugs in Clinical Development

10 Pipeline Valuation Analysis

  • 10.1 Overview
  • 10.2 Competitive Assessment
    • 10.2.1 Acute Treatment for Migraine
    • 10.2.2 Preventive Treatment for Migraine

11 Current and Future Players

  • 11.1 Overview
  • 11.2 Deal-Making Trends

12 Market Outlook

  • 12.1 Global Markets
    • 12.1.1 Forecast
    • 12.1.2 Drivers and Barriers - Global Issues
  • 12.2 US
    • 12.2.1 Forecast
    • 12.2.2 Key Events
    • 12.2.3 Drivers and Barriers
  • 12.3 5EU
    • 12.3.1 Forecast
    • 12.3.2 Key Events
    • 12.3.3 Drivers and Barriers
  • 12.4 Japan
    • 12.4.1 Forecast
    • 12.4.2 Key Events
    • 12.4.3 Drivers and Barriers

13 Appendix

  • 13.1 Bibliography
  • 13.2 Abbreviations
  • 13.3 Methodology
    • 13.3.1 Forecasting Methodology
  • 13.4 Primary Research - KOLs Interviewed for This Report
    • 13.4.1 KOLs
  • 13.5 Primary Research - Prescriber Survey
  • 13.6 About the Authors
    • 13.6.1 Analyst
    • 13.6.2 Managing Analyst
    • 13.6.3 Therapy Area Director
    • 13.6.4 Epidemiologist
    • 13.6.5 Managing Epidemiologist
    • 13.6.6 Global Director of Therapy Analysis and Epidemiology
    • 13.6.7 Global Head and EVP of Healthcare Operations and Strategy
  • Contact Us

List of Tables

List of Tables

  • Table 1: Disease Migraine: Key Metrics in the 7MM
  • Table 2: Migraine Classification from the ICHD-3
  • Table 3: Diagnostic Criteria for Migraine with Aura
  • Table 4: Diagnostic Criteria for Migraine without Aura
  • Table 5: Risk Factors and Comorbidities for Migraine
  • Table 6: Treatment Guidelines for Disease Migraine
  • Table 7: Most Prescribed Drugs for Migraine by Class in the 7MM
  • Table 8: Migraine Market - Global Drivers and Barriers, 2020-2030
  • Table 9: Key Events Impacting Sales for Migraine in the US, 2020-2030
  • Table 10: Migraine Market - Drivers and Barriers in the US, 2020-2030
  • Table 11: Key Events Impacting Sales for Migraine in the 5EU, 2020-2030
  • Table 12: Migraine Market - Drivers and Barriers in the 5EU, 2020-2030
  • Table 13: Key Events Impacting Sales for Migraine in Japan, 2020-2030
  • Table 14: Migraine Market - Drivers and Barriers in Japan, 2020- 2030
  • Table 15: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

List of Figures

  • Figure 1: Global Sales Forecast by Country for Migraine in 2020 and 2030
  • Figure 2: Analysis of the Company Portfolio Gap in Migraine During the Forecast Period
  • Figure 3: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC for Acute Migraine Treatment, Imitrex.
  • Figure 4: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against SOC for Preventive Migraine Treatment, generic propranolol.
  • Figure 5: Pathophysiology of a Migraine
  • Figure 6: 7MM, 12-Month Total Prevalence of Migraine, Men and Women, %, Ages ≥18 Years, 2020
  • Figure 7: 7MM, Sources Used and Not Used to Forecast the 12-Month Total Prevalent Cases of Migraine
  • Figure 8: 7MM, Sources Used to Forecast the 12-Month Total Prevalent Cases of Migraine by Frequency
  • Figure 9: 7MM, Sources Used to Forecast the 12-Month Total Prevalent Cases of Migraine by Type
  • Figure 10: 7MM, Sources Used to Forecast the Diagnosis Rate of Migraine
  • Figure 11: 7MM, 12-Month Total Prevalent Cases of Migraine, N, Both Sexes, Ages ≥18 Years, 2020
  • Figure 12: 7MM, 12-Month Total Prevalent Cases of Migraine by Age, N, Both Sexes, 2020
  • Figure 13: 7MM, 12-Month Total Prevalent Cases of Migraine by Sex, N, Ages ≥18 Years, 2020
  • Figure 14: 7MM, 12-Month Total Prevalent Cases of Migraine by Frequency, N, Both Sexes, Ages ≥18 Years, 2020
  • Figure 15: 7MM, 12-Month Total Prevalent Cases of Migraine by Type, N, Both Sexes, Ages ≥18 Years, 2020
  • Figure 16: 7MM, 12-Month Diagnosed Prevalent Cases of Migraine, N, Both Sexes, Ages ≥18 Years, 2020
  • Figure 17: Unmet Needs and Opportunities in Migraine
  • Figure 18: Overview of the Development Pipeline in Migraine
  • Figure 19: Key Late-Stage Trials for the Promising Pipeline Agents that GlobalData Expects to Be Licensed for Migraine in the 7MM During the Forecast Period
  • Figure 20: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC for Acute Migraine Treatment, Imitrex.
  • Figure 21: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against SOC for Preventive Migraine Treatment, generic propranolol.
  • Figure 22: Analysis of the Company Portfolio Gap in Migraine During the Forecast Period
  • Figure 23: Global (7MM) Sales Forecast by Country for Migraine in 2020 and 2030
  • Figure 24: Global (7MM) Sales Forecast by Drug Class for Migraine in 2020 and 2030
  • Figure 25: Sales Forecast by Class for Migraine in the US in 2020 and 2030
  • Figure 26: Sales Forecast by Class for Migraine in the 5EU in 2020 and 2030
  • Figure 27: Sales Forecast by Class for Migraine in the Japan in 2020 and 2030